mFluiDx, Inc.

Berkeley, CA · Medtech · Private

Fully automated point-of-care nucleic acid diagnostic device using vacuum-diffusion microfluidics for rapid detection of infectious diseases and drug resistance

mfluidx.com →
Grants
$2.6M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Point-of-care microfluidic nucleic acid amplification test for primary care$298,823
Federal grantDepartment of Health and Human Services · Phase II · Point-of-care Microfluidic Diagnostic for Outpatient Clinics$1,499,999
Federal grantDepartment of Health and Human Services · Phase II · Point-of-care Microfluidic Diagnostic for Outpatient Clinics$797,077
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1989Theator Inc.—$38M
1990ReVivo Medical, LLC——
1991SymKardia, Inc.—$500K
1992mFluiDx, Inc.——
1993Therapeutic Articulations, LLC——
1994Axonova Medical LLC——
1995UrSure Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Consumable Microfluidic Molecular Diagnostic Devices, Associated Systems, And Methods Of Manufacture, Including Roll-to-roll Manufacturing Processesapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.